Navigation Links
Michael J. Fox Foundation Commits Up to $12 Million for Targeted Parkinson's Therapeutic Development in 2010
Date:9/15/2009

NEW YORK, Sept. 15 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation has committed up to $12 million in 2010 funding for prioritized research toward transformative treatments and a cure for Parkinson's disease.

Funding is open to academic and industry researchers through the Foundation's Pipeline Programs, which consist of three annually recurring initiatives, known collectively as The Edmond J. Safra Core Programs for PD Research, as well as the industry-exclusive Therapeutics Development Initiative. The Foundation seeks investigator-initiated proposals focused on the following critical points along the translational pathway to new therapies for Parkinson's disease:

  • Testing Novel Hypotheses: Quick support for high-risk, high-reward projects with little to no existing preliminary data, but potential to significantly impact our understanding or treatment of PD.
  • Validating Novel Targets: Support for work demonstrating whether modulation of a novel biological target has impact in a PD-relevant pre-clinical model -- an essential step to the development of potential targeted therapies.
  • Catalyzing and Expanding Preclinical Development: Industry-exclusive support for preclinical development of Parkinson's disease therapies with potential to fundamentally alter disease course and/or improve treatment of symptoms above and beyond current standards of care.
  • Clinically Testing Novel Therapies: Support for clinical testing of promising PD therapies that may significantly and fundamentally improve treatment of PD.

"The Pipeline Programs reflect our Foundation's portfolio approach to supporting the most promising work across multiple stages of development," said Katie Hood, the Foundation's CEO. "The programs are complementary expressions of our mission to prioritize and aggressively drive research that can significantly improve patients' quality of life -- sooner rather than later."

Brief program descriptions follow. Full details are available at www.michaeljfox.org/research.

Rapid Response Innovation Awards, An Edmond J. Safra Core Program for PD Research

Total available funding: $2 million

No deadline; applications accepted at any time

Rapid Response Innovation Awards provide up to $75,000 for projects with little to no existing preliminary data, but with potential to significantly impact understanding or treatment of Parkinson's disease. MJFF is eager to fund high-risk, high-reward projects tackling critical scientific roadblocks to open new avenues for PD therapy development. Research proposals may be submitted at any time and funding decisions are made within six weeks of receiving the application.

Target Validation, An Edmond J. Safra Core Program for PD Research

Total available funding: $2 million (in two funding rounds)

Deadlines: ROUND 1: 6 p.m. ET, Tuesday, December 15, 2009;

ROUND 2: 6 p.m. ET, Tuesday, June 1, 2010

Funding anticipated: ROUND 1: June 2010

ROUND 2: December 2010

Target Validation provides awards of up to $250,000 to validate the therapeutic potential of scientific discoveries and push them one step closer to the clinic. While research continues to identify new genetic, cellular and biological targets for therapeutic intervention to benefit PD patients, the translation of these discoveries into practical treatments requires additional applied work. Target Validation funds this work with the ultimate goal of 'de-risking' potential investment in the most promising targets by biotech and pharmaceutical companies, who are generally best-suited to carry promising therapies forward into the clinic.

Therapeutics Development Initiative

Total available funding: $5 million, exclusively to industry

Deadline: 6 p.m. ET, Monday, January 18, 2010; Spring 2010 deadline TBA

Funding Anticipated: June 2010

The Therapeutics Development Initiative (TDI) seeks to stimulate preclinical Parkinson's disease research projects of up to two years duration at for-profit institutions. There is no pre-set budget limitation for applications under this initiative. The program prioritizes key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing.

Clinical Intervention Awards, An Edmond J. Safra Core Program for PD Research Total available funding: $3 million

Deadline: 6 p.m. ET, Tuesday, December 15, 2009

Funding anticipated: July 2010

The Clinical Intervention Awards drive clinical intervention trials of promising therapeutic approaches with potential to significantly improve the treatment of PD. Ideal proposals will focus on tests of novel treatments that can slow or halt disease progression, or that can greatly reduce PD motor and non-motor symptoms beyond (and without the complications of) current standards of care. There is no pre-set budget limitation for applications under this initiative.

Applications for all programs must be submitted through www.michaeljfox.org.

Pre-proposals (required for all programs except Rapid Response Innovation Awards) will be reviewed by the Foundation's scientific staff and a panel of scientific experts. Applicants whose pre-proposals meet the review criteria will be invited to submit full proposals. Conference calls with MJFF Research Programs staff to further clarify the aims and goals of the Pipeline Programs will be held in advance of the application deadline. Date and time details for each conference call are available at www.michaeljfox.org.

Additional research funds for the coming year will be announced at later dates under the Foundation's 2010 Critical Challenges initiatives -- programs that provide funding for top MJFF research priorities and areas of particular emphasis.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease through an aggressively funded research agenda. The Foundation has funded $149 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/4/2017)... , Aug. 4, 2017 The search ... shortly after a physician/patient consult has long been the ... was a notable focus of the largest meeting of ... according to healthcare market research firm Kalorama Information.  The ... testing (POCT) offerings or related supplies and software were ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... uses UVC light energy to kill deadly pathogens such as C. diff , MRSA, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... ... The Industrial Designers Society of America (IDSA) hosted the ... Aug. 19, 2017 in Atlanta, GA—revealing which 25 designs won Gold and which 52 ... See all the winners at http://www.idsa.org/awards/idea/gallery . , “I hope you’re as excited ...
(Date:8/20/2017)... ... August 20, 2017 , ... State Farm Neighborhood Assist® has named The ... a $25,000 grant. If the initiative wins, Gals Lead – Dream Queen Foundation’s signature ... Tri-County area of St. Mary’s, Calvert and Charles Counties. The program could potentially impact ...
(Date:8/19/2017)... ... 18, 2017 , ... Western University of Health Sciences will host a special ... new Center for Innovation on Wednesday, September 6, 2017. , The symposium will be ... by a technology exhibition from 1 to 3 p.m. showcasing virtual reality education technology, ...
(Date:8/19/2017)... New York, New York (PRWEB) , ... August ... ... Fruit Street Health has announced that it is the first organization with pending ... the CDC’s National Diabetes Prevention Program (“DPP”) via group telehealth classes and live ...
(Date:8/19/2017)... ... , ... Yesterday, the President of the United States retracted his condemnation of ... not two sides to hatred, bigotry, discrimination, and a white supremacy nationalist agenda. ... against all forms of such hatred and discrimination in this country and globally. ...
Breaking Medicine News(10 mins):